Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFUM: Gefitinib in Caucasian EGFR+ NSCLC
NCT01203917Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2010
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 4, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate (Investigator) up to 23 months. Started Sep 2010; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01203917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203917.